Palbociclib and ribociclib are cyclin-dependent kinase (CDK) 4/6 inhibitors and are indicated as a treatment option for patients with HR+, HER2- advanced breast cancer, either as a first-line therapy combined with an aromatase inhibitor or as second-line therapy in combination with fulvestrant [33]. This evidence concerns the gene CYP19A1 and breast carcinoma.